Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Dipeptidyl Peptidase 4 Inhibitors Market

Dipeptidyl Peptidase 4 Inhibitors Market Share

Report ID: GMI11600
Published Date: Sep 2024
Report Format: PDF

Download Free Sample

Dipeptidyl Peptidase 4 Inhibitors Market Share

The market is characterized by a highly competitive landscape, with key players vying for market share through innovation and strategic initiatives. Leading companies such as Merck & Co., Inc., AstraZeneca plc, Eli Lilly and Company, Novartis AG, and Sanofi hold significant market shares due to their well-established diabetes treatment portfolios and strong global presence. These firms are highly competitive in advancing research and development to innovate new DPP-4 inhibitors and expand their therapeutic uses.

Dipeptidyl Peptidase 4 Inhibitors Market Companies

Prominent players operating in the dipeptidyl peptidase 4 inhibitors industry include:

AstraZeneca plc
Bristol Myers Squibb Company
Boehringer Ingelheim International GmbH
Eli Lilly and Company
Merck & Co., Inc.
Mitsubishi Tanabe Pharma Corporation
Novartis AG
Pfizer, Inc.
Takeda Pharmaceuticals Company Limited
Sanofi
Sanwa Kagaku Kenkyusho Co., Ltd.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The dipeptidyl peptidase 4 inhibitors industry was valued at USD 11.3 billion in 2023 and is projected to grow at a 3.5% CAGR from 2024 to 2032. This growth is driven by the rising prevalence of type 2 diabetes worldwide, increasing the demand for effective treatments.

Based on drug type, the market is classified into sitagliptin, saxagliptin, linagliptin, alogliptin, vildagliptin, and other drug types. The sitagliptin segment dominated the market with 40.4% of the market share in 2023.

The North American market for dipeptidyl peptidase 4 inhibitors recorded USD 4.6 billion in 2023 and is expected to witness growth at a 3.4% CAGR during the analysis period.

Prominent companies in the dipeptidyl peptidase 4 inhibitors market include AstraZeneca plc, Bristol Myers Squibb Company, Boehringer Ingelheim International GmbH, Eli Lilly and Company, Merck & Co., Inc., Mitsubishi Tanabe Pharma Corporation, Novartis AG, Pfizer, Inc., Takeda Pharmaceuticals Company Limited, Sanofi, and Sanwa Kagaku Kenkyusho Co., Ltd.